Projects / Antibodies in immune-mediated diseases / Diabetes

Design and synthesis of new peptide scaffold presenting AGEs as diagnostic tool to monitor biomarkers in diabetes


In collaboration with:

CNR ISTM, Padua, Italy

Piero Traldi

University of Padua, Dipartimento Sci. Med. & Chirurg., Padua, Italy

A Lapolla

Laboratory for Translational Research, Harvard Medical School and  Department of Medicine, Brigham and Women’s Hospital, Boston, USA

Michael Chorev

Advanced glycation end products (AGEs) are a heterogeneous group of molecules formed from the nonenzymatic reaction of reducing sugars with free amino groups of proteins, lipids, and nucleic acids. A large body of evidence suggests that AGEs are important pathogenetic mediators of almost all diabetes complications. Two principal mechanisms are described to explain AGEs toxicity: the cross-linking of protein leading to alterations in the tissues, and the interaction with cell surface receptors for advanced glycation end products (RAGE) leading to pro-inflammatory events.Some compounds, i.e. Ne-carboxymethyl-lysine, pentosidine, or methylglyoxal derivatives, are well-characterized and widely studied AGEs. Based on the structure of multiple antigenic peptide (MAP) system, we developed new peptide scaffold by solid-phase peptide synthesis (SPPS) presenting AGEs. Such peptides can bear identical or different AGEs on the branch and used for biomarker diagnosis of diabetes in sera patients by indirect ELISA test.